This resource provides links to legislation and regulations related to medical countermeasures.
This work is intended to serve as a resource of pharmaceutical options that may be available to communities when faced with a mass human exposure to a nerve agent and inadequate supplies of medical countermeasures.
The US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) announced a strategic partnership with Genentech. The company and ASPR’s Biomedical Advanced Research and Development Authority (BARDA) will focus first on developing a first-in-class therapeutic for hospitalized influenza patients and a treatment for lung injuries caused by inhaling sulfur mustard gas.
Ensuring appropriate distribution and dispensing of medical countermeasures can be logistically complex, but coordinated planning between local, state, and federal agencies facilitates an efficient public health response.
Biodefense vaccines are destined to be stockpiled for periods of time and deployed in the event of a public health emergency.
Nationwide, the repository contains enough medical countermeasures to add up to more than 133,995 pallets.
There is significant interest in opioids and their impact on the population, from the public health crisis of substance abuse, to events like the Dubrovka Theater siege.
The first doses of ANTHIM® (obiltoxaximab) Injection, a treatment for inhalational anthrax, has been delivered to the US Strategic National Stockpile.
The ability to conduct clinical research in a disease outbreak setting has significant advantages.
The 2001 anthrax attacks demonstrated the need for early public health countermeasures and mitigation capabilities.